Disrupting Tumor Lactate Homeostasis to Sensitize Chemo-Immunotherapy Using a Glucose-Disguised Lactate Interceptor
Source abstract
Abstract
Aberrantly elevated lactate flux in tumors is increasingly recognized as a key driver of metabolic symbiosis, immunosuppression, and, ultimately, immunogenic chemotherapy resistance. Here, we propose a precise lactate homeostasis modulation strategy that selectively intercepts intracellular lactate molecules in highly glycolytic tumor cells. Targeting monocarboxylate transporter 4 (MCT4), a key lactate efflux transporter overexpressed in tumor cells, we developed a glucose-disguised delivery system for precise transport of regulatory molecules into glycolysis-dependent tumor cells. By modulating lactate-mediated crosstalk between heterogeneous tumor subpopulations (glycolysis-dependent and lactate-consuming cells) and immune cells, this strategy effectively disrupts lactate-driven metabolic cooperation within the tumor niche, which may contribute to overcoming lactate-associated resistance to chemo-immunotherapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Cancer, Hypoxia, and Metabolism · Nanoplatforms for cancer theranostics · Immune cells in cancer
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutics, School of Pharmacy
Fudan University
Key Laboratory of Smart Drug Delivery, Ministry of Education
State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science
Department of Digestive Diseases, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital
Fujian Medical University
Funding
Shanghai Municipal Youth Science and Technology Star Project · National Natural Science Foundation of China · Pingyuan Laboratory · ZJLab
References (35)
Show source-provided references
1. 10.1038/s41568-021-00378-610.1038/s41568-021-00378-6 ↗
2. 10.1126/science.aaw547310.1126/science.aaw5473 ↗
3. 10.1038/s42255-020-00317-z10.1038/s42255-020-00317-z ↗
4. 10.1016/j.devcel.2020.06.01810.1016/j.devcel.2020.06.018 ↗
5. 10.1016/j.cmet.2019.08.01310.1016/j.cmet.2019.08.013 ↗
6. 10.1073/pnas.121955511010.1073/pnas.1219555110 ↗
7. 10.1038/s41568-020-0273-y10.1038/s41568-020-0273-y ↗
8. 10.1016/j.cmet.2020.03.00110.1016/j.cmet.2020.03.001 ↗
9. 10.1016/j.cmet.2017.06.01610.1016/j.cmet.2017.06.016 ↗
10. 10.1016/j.canlet.2024.21689610.1016/j.canlet.2024.216896 ↗
11. 10.1038/s41590-024-01985-910.1038/s41590-024-01985-9 ↗
12. 10.1002/advs.20230566210.1002/advs.202305662 ↗
13. 10.1038/s41392-022-01206-510.1038/s41392-022-01206-5 ↗
14. 10.1016/j.cmet.2018.03.00810.1016/j.cmet.2018.03.008 ↗
15. 10.1124/pr.119.01876210.1124/pr.119.018762 ↗
16. 10.1016/j.celrep.2018.11.04310.1016/j.celrep.2018.11.043 ↗
17. 10.1002/j.2040-4603.2013.tb00533.x10.1002/j.2040-4603.2013.tb00533.x ↗
18. 10.1016/j.pharmthera.2021.10786210.1016/j.pharmthera.2021.107862 ↗
19. 10.3389/fcell.2020.0065110.3389/fcell.2020.00651 ↗
20. 10.2174/13816121279950490210.2174/138161212799504902 ↗
21. 10.1158/1535-7163.MCT-17-053510.1158/1535-7163.MCT-17-0535 ↗
22. 10.1038/s41575-021-00431-710.1038/s41575-021-00431-7 ↗
23. 10.1007/s00109-015-1307-x10.1007/s00109-015-1307-x ↗
24. 10.3390/cancers1211324410.3390/cancers12113244 ↗
25. 10.1113/JP28095510.1113/JP280955 ↗
26. 10.1038/s41419-022-05111-110.1038/s41419-022-05111-1 ↗
27. 10.1038/s41577-020-0406-210.1038/s41577-020-0406-2 ↗
28. 10.1073/pnas.121955511010.1073/pnas.1219555110 ↗
29. 10.1101/2023.07.24.55028910.1101/2023.07.24.550289 ↗
30. 10.1038/s41467-022-28618-910.1038/s41467-022-28618-9 ↗
31. 10.1038/s41392-023-01332-810.1038/s41392-023-01332-8 ↗
32. 10.1016/j.cell.2023.11.02210.1016/j.cell.2023.11.022 ↗
33. 10.1002/adma.20230958210.1002/adma.202309582 ↗
34. 10.1016/j.cell.2024.04.00210.1016/j.cell.2024.04.002 ↗
35. 10.1038/s41586-024-07620-910.1038/s41586-024-07620-9 ↗